- Volume 14 Issue 5
DOI QR Code
Differences in Epidermal Growth Factor Receptor Gene Mutations and Relationship with Clinicopathological Features in NSCLC Between Uygur and Han Ethnic Groups
- Zhang, Yan (Medical Pulmonology, Tumor Hospital affiliated to Xinjiang Medical University) ;
- Wang, Qiang (Medical Pulmonology, Tumor Hospital affiliated to Xinjiang Medical University) ;
- Han, Zhi-Gang (Medical Pulmonology, Tumor Hospital affiliated to Xinjiang Medical University) ;
- Shan, Li (Medical Pulmonology, Tumor Hospital affiliated to Xinjiang Medical University)
- Published : 2013.05.30
Objective: To investigate differences in mutations of epidermal growth factor receptor (EGFR) gene and relationships with clinicopathological features in patients with non-small cell lung cancer (NSCLC) between Uygur and Han ethnic groups. Methods: The Scorpions amplification refractory mutation system (Scorpions ARMS) was used to measure mutations in exons 18, 19, 20 and 21 of the EGFR gene in paraffin-embedded tumor tissue from NSCLC cases, and statistical analysis was performed to investigate links with clinicopathological features in different histological types of NSCLC. Results: Results from ARMS testing showed EGFR mutations in tumor tissues from six (6) of 50 NSCLC patients of Uygur ethnic group, with a positive rate of 12.0%; four of them (4) had exon 19 deletion in EGFR, and two (2) had L858R point mutation in exon 21 of EGFR. Statistically significant difference was noted in EGFR genetic mutation between adenocarcinoma and non-adenocarcinoma (P < 0.05), but no differences with gender, age group, smoking status, or stage (P > 0.05). EGFR mutations were detected in tumor tissues from 27 of 49 NSCLC patients of Han ethnic group, with a positive rate of 55.1%; 19 of them had exon 19 deletions, seven (7) had L858R point mutations in exon 21 of EGFR and one (1) had mutations in both exon 18 G719X and exon 20 T790M of EGFR. Statistically significant differences were noted in EGFR genetic mutations between genders and between adenocarcinoma and non-adenocarcinoma (P<0.05), but not with age group, smoking status, or stage (P > 0.05). Conclusion: Statistically significant differences were noted in the positive rates of EGFR genetic mutations in NSCLC patients between Uygur and Han ethnic groups, with lower positive rates for the Uygur cases.
- Huang SF, Liu HP, Li LH (2004). High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancer related to gefitinib responsiveness in Taiwan. Clin Cancer Res, 10, 8195-203. https://doi.org/10.1158/1078-0432.CCR-04-1245
- Inal A, Kaplan MA, Kucukoner M, et al (2012). Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution. Asian Pac J Cancer Prev, 13, 1281-4. https://doi.org/10.7314/APJCP.2012.13.4.1281
- Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
- Lynch TJ, Bell DW, Sordella R (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39. https://doi.org/10.1056/NEJMoa040938
- Marchetti A, Martella C, Felicioni L (2005). EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol, 23, 857-65. https://doi.org/10.1200/JCO.2005.08.043
- MILLER VA, O'CONNOR P, SOH C (2009). A randomized, double-blind, placeb controlled, phase IIIb trial (atlas) comparing bevacizumab(B) therapy with or without erlotinib(E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic nonsmall cell lung. J Clin Oncol, 27, abstrLBA8002.
- Mu XL, Li LY, Zhang XT (2005). Gefitinib-sensitive mutations of the epidermal growth factor receptor thyosine domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res, 11, 4289-94. https://doi.org/10.1158/1078-0432.CCR-04-2506
- Paez JG, Janner PA, Lee JC(2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500. https://doi.org/10.1126/science.1099314
- Pao W, Miller V, Zakowski M (2004). EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101, 13306-11. https://doi.org/10.1073/pnas.0405220101
- Qin BM, Chen X, Zhu JD (2005). Identification of EGFR kinase domain mutaitions among lung cancer patients in China:implication for targeted cancer therapy. Cell Res, 15, 212-7. https://doi.org/10.1038/sj.cr.7290289
- Shigematsu H, Lin L, Takahashi T (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 97, 339-46. https://doi.org/10.1093/jnci/dji055
- Tokumo M, Toyooka S, Kiura K (2005). The relationship between epidermal gorwth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res, 11, 1167-73.
- Xiao H, Ding J, Gao S, Yang S, Huang Y (2011). Never smokers with lung cancer: analysis of genetic variants. Asian Pac J Cancer Prev, 12, 2807-9.
- Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol, 12, 735-42. https://doi.org/10.1016/S1470-2045(11)70184-X
- Serum Carcinoembryonic Antigen Levels before Initial Treatment are Associated with EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma Patients vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3927
- Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.965
- Mortality outcomes of low-dose computed tomography screening for lung cancer in urban China: a decision analysis and implications for practice vol.36, pp.1, 2017, https://doi.org/10.1186/s40880-017-0221-8